Antiverse · Insights Wireframe
Announcement Series A closed at $9.3M · Research agreement with the Cystic Fibrosis Foundation →
Discuss your target Partnership options
Insights

The intelligence hub
for GPCR therapeutics.

Whitepapers, CEO bylines, field commentary and the monthly GPCR Intelligence briefing. Published because the field needs it — and read by exactly the people we need to reach.

Subscribe to GPCR Intelligence Read the whitepaper
Page purpose — strategy §Thought Leadership. Pharma executives read STAT, Endpoints, Nature Biotech. They don't read sponsored content. This page is the owned home for work that earns attention, and the hub the ABM programme points at.
01Flagship
Whitepaper · gated

GPCR Antibody Discovery:
State of the Art 2026

The field landscape and Antiverse's position within it — authored by Ben Holland and the scientific team. Covers why 400+ receptors remain undruggable, what has changed, and what will change next. Thought leadership that doubles as lead capture.

Download Email required
Cover — whitepaper
Lead magnet — strategy §Content and Downloads. The gate is the point: this is how the Target 120 list gets built and enriched.
02CEO byline programme

One substantive article per month.

Opinion pieces on the field, not product announcements. Published in the outlets pharma executives already read, and surfaced here.

GEN

Why 400+ GPCRs remain undruggable — and what will change that

Murat Tunaboylu · opinion

Read →
Drug Target Review

The difference between antibody discovery and antibody engineering

Murat Tunaboylu · opinion

Read →
Manufacturing Chemist

Placeholder — existing byline article title

Murat Tunaboylu · opinion

Read →
DDW

Placeholder — existing byline article title

Murat Tunaboylu · opinion

Read →
Antiverse

Placeholder — original commentary published here first

Antiverse scientific team

Read →
Bylines — strategy §Thought Leadership. These articles already exist and are currently buried. Surfacing them costs nothing and immediately makes the company look active. The gap is volume, consistency, and targeting outlets executives actually read.
03Owned channel
Newsletter — strategy §Thought Leadership. This is the highest-leverage owned asset on the site: it converts one-time visitors into a recurring, opted-in audience of exactly the right people, and it positions Antiverse as the intelligence hub for its niche rather than a vendor in it.
04Podcast

Future of Drug Discovery

Every recording is a 90-minute meeting with a target. The format works; the guest list is where the leverage is.

Episode artwork
Episode

Placeholder — guest name & title

One-line episode summary.

Episode artwork
Episode

Placeholder — guest name & title

One-line episode summary.

Episode artwork
Episode

Placeholder — guest name & title

One-line episode summary.

Podcast — strategy §Thought Leadership. Target guests: SVPs from AstraZeneca, Roche, Sanofi. A guest is three things at once — a warm relationship, a shared audience, and a piece of content their network distributes for you.

Get the monthly briefing.

GPCR Intelligence. One email a month, no product pitches.

Subscribe See the platform